Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.71 |
| ▸ | ATM | Q13315 | 2/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | HCK | P08631 | 2/20 | 0.69 |
| ▸ | NR2C2 | P49116 | 2/20 | 0.69 |
| ▸ | KIT | P10721 | 2/20 | 0.68 |
| ▸ | CLK1 | P49759 | 1/20 | 0.67 |
| ▸ | BRAF | P15056 | 2/20 | 0.64 |
| ▸ | EGFR | P00533 | 1/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.64 |
| ▸ | MAP3K7 | O43318 | 5/20 | 0.64 |
| ▸ | MAP4K2 | Q12851 | 5/20 | 0.64 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 0.64 |
| ▸ | FES | P07332 | 2/20 | 0.64 |
| ▸ | FER | P16591 | 2/20 | 0.64 |
| ▸ | GCK | P35557 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2226481 | 0.96 | HTT (0.68) | HTTATMMAPK1HCKNR2C2 | |
| SCHEMBL4254627 | 0.92 | KIT (0.79) | KITBRAFEGFR | |
| SCHEMBL20568434 | 0.90 | HTT (0.62) | HTTATMMAPK1HCKNR2C2 | |
| SCHEMBL4255712 | 0.90 | KIT (0.64) | HTTATMMAPK1HCKNR2C2 | |
| SCHEMBL4256157 | 0.90 | KIT (0.64) | HTTATMMAPK1HCKNR2C2 | |
| SCHEMBL30309801 | 0.89 | KIT (0.69) | HTTATMMAPK1HCKNR2C2 | |
| SCHEMBL26680109 | 0.89 | KIT (0.69) | HTTATMMAPK1HCKNR2C2 | |
| SCHEMBL4260023 | 0.89 | HTT (0.66) | HTTATMMAPK1HCKNR2C2 | |
| SCHEMBL16236899 | 0.89 | KIT (0.86) | HTTATMMAPK1HCKNR2C2 | |
| SCHEMBL3561769 | 0.89 | KIT (0.76) | KITBRAFEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589101-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2009-09-15 | — | — | US | claimed |
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-23 | — | — | US | claimed |
| US-20080287432-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-11-20 | — | — | US | claimed |
| EP-1758892-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2012-10-17 | — | — | EP | disclosed |
| US-8183248-B2 | Substituted pyrrolo[2,3-d]pyrimidines and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-05-22 | — | — | US | disclosed |
| US-8183248-B2 | Substituted pyrrolo[2,3-d]pyrimidines and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-05-22 | — | — | US | disclosed |
| US-8183248-B2 | Substituted pyrrolo[2,3-d]pyrimidines and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-05-22 | — | — | US | disclosed |
| EP-1891066-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-12-22 | — | — | EP | disclosed |
| EP-1891066-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-12-22 | — | — | EP | disclosed |
| US-7745437-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-06-29 | — | — | US | disclosed |
| US-7745437-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-06-29 | — | — | US | disclosed |
| US-7589101-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2009-09-15 | — | — | US | disclosed |
| US-20090118273-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2009-05-07 | — | — | US | disclosed |
| US-20090118273-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2009-05-07 | — | — | US | disclosed |
| US-20090118273-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2009-05-07 | — | — | US | disclosed |
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-23 | — | — | US | disclosed |
| US-20080287432-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-11-20 | — | — | US | disclosed |
| EP-1891066-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2008-02-27 | — | — | EP | disclosed |
| US-20070225286-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2007-09-27 | — | — | US | disclosed |
| WO-2006124462-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ABL1, BCR, PDGFRB | HTT 1435/4885ATM 698/4885MAPK1 235/4885 |
| US-20080287432-A1 | Compounds and Compositions as Protein Kinase Inhibitors | AURKC, PTK2B, FRK | HTT 3023/4885ATM 485/4885MAPK1 497/4885 |
| US-20090118273-A1 | Compounds and Compositions as Protein Kinase Inhibitors | SRC, FYN, SYK | HTT 3710/4885ATM 483/4885MAPK1 213/4885 |
| US-20070225286-A1 | Compounds and Compositions as Protein Kinase Inhibitors | BMX, PTK2B, SRC | HTT 2165/4885ATM 848/4885MAPK1 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.